A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Lionel Uwer; José Hureaux; Florian Guisier; Delphine Carmier; Jeannick Madelaine; Josiane Otto; Valérie Gounant; Patrick Merle; Pierre Mourlanette; Olivier Molinier; Aldo Renault; Audrey Rabeau; Martine Antoine; Marc G. Denis; Sébastien Bommart; Alexandra Langlais; Franck Morin; Pierre-Jean Souquet

doi:10.1016/j.jtho.2019.01.008

Back

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Journal article

Peer reviewed

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Lionel Uwer, José Hureaux, Florian Guisier, Delphine Carmier, Jeannick Madelaine, Josiane Otto, …

Journal of Thoracic Oncology, Vol.14(5), pp.903-913

05/2019

DOI: https://doi.org/10.1016/j.jtho.2019.01.008

PMID: 30664989

Abstract

SCLC

Programmed cell death ligand 1

Chemotherapy

Atezolizumab

This randomized phase II trial aimed at evaluating the engineered programmed cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line platinum-etoposide chemotherapy.

Files and links (2)

url

Find in HALView

url

https://doi.org/10.1016/j.jtho.2019.01.008View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Creators - without role: Jean-Louis Pujol - Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier - IRCM
Laurent Greillier - Aix-Marseille Université
Clarisse Audigier-Valette
Denis Moro-Sibilot - Centre Hospitalier Universitaire de Grenoble
Lionel Uwer - Institut de Cancérologie de Lorraine
José Hureaux - Université d'Angers
Florian Guisier - Université de Rouen Normandie
Delphine Carmier - Centre Hospitalier Universitaire de Tours
Jeannick Madelaine - Centre Hospitalier Universitaire de Caen Normandie
Josiane Otto - Centre Antoine Lacassagne
Valérie Gounant - Hôpital Bichat-Claude-Bernard
Patrick Merle
Pierre Mourlanette - Clinique des Cèdres
Olivier Molinier - Centre Hospitalier du Mans
Aldo Renault - Centre Hospitalier De Pau
Audrey Rabeau - Université Toulouse III - Paul Sabatier
Martine Antoine - Hôpitaux Universitaires Paris-Ouest
Marc G. Denis - Nantes Université
Sébastien Bommart - Université de Montpellier, Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
Alexandra Langlais - Intergroupe Francophone de Cancérologie Thoracique
Franck Morin - Intergroupe Francophone de Cancérologie Thoracique
Pierre-Jean Souquet
Publication Details: Journal of Thoracic Oncology, Vol.14(5), pp.903-913
Identifiers: 99107898509311
Academic Unit: Institut de Recherche en Cancérologie de Montpellier - IRCM; Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
Language: English
Resource Type: Journal article
Local Fields: hal-02570679